These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 9237717)

  • 1. Human immunodeficiency virus type 1 gp41 binds to Candida albicans via complement C3-like regions.
    Würzner R; Gruber A; Stoiber H; Spruth M; Chen YH; Lukasser-Vogl E; Schwendinger MG; Dierich MP
    J Infect Dis; 1997 Aug; 176(2):492-8. PubMed ID: 9237717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 and its transmembrane protein gp41 bind to different Candida species modulating adhesion.
    Gruber A; Lell CP; Spruth M; Lass-Flörl C; Speth C; Stoiber H; Hube B; Coleman D; Polonelli L; Dierich MP; Würzner R
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):77-83. PubMed ID: 12770763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of several complement proteins with gp120 and gp41, the two envelope glycoproteins of HIV-1.
    Stoiber H; Ebenbichler C; Schneider R; Janatova J; Dierich MP
    AIDS; 1995 Jan; 9(1):19-26. PubMed ID: 7893437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 rsgp41 depends on calcium for binding of human c1q but not for binding of gp120.
    Stoiber H; Ebenbichler CF; Thielens NM; Arlaud GJ; Dierich MP
    Mol Immunol; 1995 Apr; 32(5):371-4. PubMed ID: 7739575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 gp160 and gp41 binding to Candida albicans selectively enhances candidal virulence in vitro.
    Gruber A; Lukasser-Vogl E; Borg-von Zepelin M; Dierich MP; Würzner R
    J Infect Dis; 1998 Apr; 177(4):1057-63. PubMed ID: 9534982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The C domain of HIV-1 gp41 binds the putative cellular receptor protein P62.
    Chen YH; Xiao Y; Wu W; Yang J; Sui S; Dierich MP
    AIDS; 1999 Jun; 13(9):1021-4. PubMed ID: 10397530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 gp41 by N-domain binds the potential receptor protein P45.
    Xiao Y; Wu W; Dierich MP; Chen Y
    Int Arch Allergy Immunol; 2000 Mar; 121(3):253-7. PubMed ID: 10729785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Further characterization of the interaction between the C1q subcomponent of human C1 and the transmembrane envelope glycoprotein gp41 of HIV-1.
    Thielens NM; Bally IM; Ebenbichler CF; Dierich MP; Arlaud GJ
    J Immunol; 1993 Dec; 151(11):6583-92. PubMed ID: 8245486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The human immunodeficiency virus type 1 transmembrane gp41 protein is a calcium-binding protein and interacts with the putative second-receptor molecules in a calcium-dependent manner.
    Ebenbichler CF; Stoiber H; Schneider R; Patsch JR; Dierich MP
    J Virol; 1996 Mar; 70(3):1723-8. PubMed ID: 8627693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 gp41 selectively inhibits spontaneous cell proliferation of human cell lines and mitogen- and recall antigen-induced lymphocyte proliferation.
    Chen YH; Christiansen A; Dierich MP
    Immunol Lett; 1995 Nov; 48(1):39-44. PubMed ID: 8847089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface proteins binding to recombinant soluble HIV-1 and HIV-2 transmembrane proteins.
    Ebenbichler CF; Röder C; Vornhagen R; Ratner L; Dierich MP
    AIDS; 1993 Apr; 7(4):489-95. PubMed ID: 8507415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of HIV-1 infection in vitro by monoclonal antibodies to the complement receptor type 3 (CR3): an accessory role for CR3 during virus entry?
    Stoiber H; Frank I; Spruth M; Schwendinger M; Mullauer B; Windisch JM; Schneider R; Katinger H; Ando I; Dierich MP
    Mol Immunol; 1997; 34(12-13):855-63. PubMed ID: 9464521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 induces complement factor C3 synthesis in astrocytes and neurons by modulation of promoter activity.
    Bruder C; Hagleitner M; Darlington G; Mohsenipour I; Würzner R; Höllmüller I; Stoiber H; Lass-Flörl C; Dierich MP; Speth C
    Mol Immunol; 2004 Feb; 40(13):949-61. PubMed ID: 14725791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human immunodeficiency virus type 1 Tat binds to Candida albicans, inducing hyphae but augmenting phagocytosis in vitro.
    Gruber A; Lell CP; Speth C; Stoiber H; Lass-Flörl C; Sonneborn A; Ernst JF; Dierich MP; Würzner R
    Immunology; 2001 Dec; 104(4):455-61. PubMed ID: 11899432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of natural polymorphism within the gp41 cytoplasmic tail of human immunodeficiency virus type 1 on the intracellular distribution of envelope glycoproteins and viral assembly.
    Lambelé M; Labrosse B; Roch E; Moreau A; Verrier B; Barin F; Roingeard P; Mammano F; Brand D
    J Virol; 2007 Jan; 81(1):125-40. PubMed ID: 17050592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of the ectodomain of the gp41 transmembrane envelope protein of human immunodeficiency virus type 1 in late steps of the membrane fusion process.
    Bär S; Alizon M
    J Virol; 2004 Jan; 78(2):811-20. PubMed ID: 14694113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic evidence for an interaction between human immunodeficiency virus type 1 matrix and alpha-helix 2 of the gp41 cytoplasmic tail.
    Murakami T; Freed EO
    J Virol; 2000 Apr; 74(8):3548-54. PubMed ID: 10729129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral properties of two trimeric recombinant gp41 proteins.
    Delcroix-Genête D; Quan PL; Roger MG; Hazan U; Nisole S; Rousseau C
    Retrovirology; 2006 Mar; 3():16. PubMed ID: 16515685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated.
    Yang C; Spies CP; Compans RW
    Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9871-5. PubMed ID: 7568235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The secreted Candida albicans protein Pra1 disrupts host defense by broadly targeting and blocking complement C3 and C3 activation fragments.
    Luo S; Dasari P; Reiher N; Hartmann A; Jacksch S; Wende E; Barz D; Niemiec MJ; Jacobsen I; Beyersdorf N; Hünig T; Klos A; Skerka C; Zipfel PF
    Mol Immunol; 2018 Jan; 93():266-277. PubMed ID: 28860090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.